cox7 Antibody

What are COX7 subunits and what is their role in mitochondrial function?

COX7 subunits (including COX7B and COX7C) are nuclear-encoded structural components of Cytochrome c oxidase (Complex IV), the terminal enzyme in the mitochondrial electron transport chain. Cytochrome c oxidase is a heteromeric complex consisting of 3 catalytic subunits encoded by mitochondrial genes and multiple structural subunits encoded by nuclear genes . These subunits play essential roles in maintaining the structural integrity of the complex and ensuring efficient electron transfer during oxidative phosphorylation.

COX7B (9 kDa) is involved in proper central nervous system development in vertebrates and functions as a terminal enzyme in the mitochondrial respiratory chain . COX7C (7 kDa) serves as another structural component that supports the catalytic core formed by the mitochondrially-encoded subunits Cox1, Cox2, and Cox3 . Both proteins are relatively small but critical for the assembly and function of the respiratory complex.

What experimental applications are most suitable for COX7 antibodies?

COX7 antibodies have demonstrated efficacy in multiple experimental applications based on validation studies. The following table summarizes the recommended applications and dilutions for COX7B and COX7C antibodies:

Both antibodies have been validated in published research with COX7C antibodies utilized in Western blot (5 publications), immunofluorescence (2 publications), and knockdown/knockout studies (1 publication) . Similarly, COX7B antibodies have been cited in Western blot applications across 4 publications . When selecting between these antibodies, researchers should consider both the application requirements and the specific tissue/cell types under investigation.

What are the optimal sample preparation techniques for COX7 antibody experiments?

Optimal sample preparation is critical for successful detection of COX7 proteins. For immunohistochemistry applications with COX7C antibodies, antigen retrieval with TE buffer (pH 9.0) is recommended, though citrate buffer (pH 6.0) can serve as an alternative . Similarly, for COX7B antibody IHC applications, TE buffer (pH 9.0) is suggested for optimal antigen retrieval .

For Western blot applications, it's important to note the observed molecular weights: COX7C typically appears at 15-28 kDa (though calculated at 7 kDa) , while COX7B appears at approximately 9 kDa, consistent with its calculated weight . This difference between calculated and observed molecular weights for COX7C suggests possible post-translational modifications or protein complexes that should be considered during experimental design and analysis.

For tissue samples, positive Western blot detection has been confirmed in:

• COX7C: mouse ovary tissue and human skeletal muscle tissue

• COX7B: mouse brain tissue, rat brain tissue, and MCF-7 cells

How should researchers troubleshoot non-specific binding or weak signals with COX7 antibodies?

When troubleshooting COX7 antibody experiments, consider the following methodological adjustments:

• Optimize antibody concentration: Both COX7B and COX7C antibodies require specific titration in each testing system. For COX7C, Western blot dilutions range from 1:500-1:2000, while COX7B typically requires more dilute preparations (1:2000-1:10000) .

• Adjust antigen retrieval methods: If weak signals appear in IHC, switching between TE buffer (pH 9.0) and citrate buffer (pH 6.0) can improve epitope accessibility .

• Consider sample-specific factors: Protein expression levels vary between tissues. For instance, COX7C has been successfully detected in mouse ovary and human skeletal muscle, while COX7B shows strong signals in brain tissues .

• Storage conditions: Both antibodies should be stored at -20°C and remain stable for one year after shipment. Improper storage can lead to antibody degradation and reduced signal intensity .

• Block non-specific binding: The storage buffer contains PBS with 0.02% sodium azide and 50% glycerol (pH 7.3), which should be considered when designing blocking solutions to minimize background signals .

How does COX7B expression correlate with cancer prognosis and immune infiltration?

The predictive capacity of COX7B expression for ESCA patient survival is robust, with an area under the ROC curve (AUC) of 0.788 . This strong correlation has enabled the development of a nomogram incorporating COX7B expression and clinical risk indicators to quantitatively predict 1-year, 3-year, and 5-year survival probabilities for ESCA patients.

Interestingly, COX7B expression also exhibits significant correlations with immune cell infiltration in the tumor microenvironment. Spearman correlation analysis revealed that COX7B expression was inversely related to several immune cell populations:

• T follicular helper cells (TFH)

• Central memory T cells (Tcm)

• Natural killer (NK) cells

• Mast cells

These findings suggest COX7B may play a critical role in regulating immune cell infiltration within tumors, potentially influencing response to immunotherapy in ESCA patients.

What factors affect in vivo antibody binding and how can researchers optimize quantitative measurements?

Antibody uptake in vivo is influenced by multiple factors that researchers must account for when designing experiments. For high-affinity antibodies like those targeting COX7 subunits, antigen expression levels significantly affect uptake, particularly at saturating doses . When using fluorophore-conjugated antibodies, researchers should verify that conjugation does not significantly alter binding affinity, as demonstrated in a study where conjugation with VivoTag 680 or Alexa Fluor 750 did not statistically change the Kd of antibodies measured by flow cytometry .

The affinity of the antibody is another critical factor. Both COX7B and COX7C antibodies are polyclonal rabbit IgG antibodies purified by antigen affinity chromatography . While specific Kd values for these antibodies aren't provided in the search results, high-affinity antibodies (subnanomolar Kd) show different targeting dynamics than moderate-affinity antibodies, particularly in relation to antigen density in tissues .

How can researchers validate the specificity of COX7 antibodies across multiple species?

COX7 antibodies show cross-reactivity across multiple species, but validation is essential for each experimental context. Both COX7B and COX7C antibodies demonstrate reactivity with human, mouse, and rat samples . Published research has cited their use with human and mouse samples, providing peer-reviewed validation of cross-species reactivity.

To rigorously validate antibody specificity across species:

• Compare observed molecular weights with predicted values for each species. For instance, COX7C has a calculated molecular weight of 7 kDa but is observed at 15-28 kDa , while COX7B shows consistency between calculated (9 kDa) and observed weight .

• Utilize positive controls from verified reactive tissues:

  • For COX7C: mouse ovary tissue, human skeletal muscle tissue, human gliomas tissue, and MCF-7 cells

  • For COX7B: mouse brain tissue, rat brain tissue, MCF-7 cells, and mouse heart tissue

• Perform knockdown/knockout validation studies. The COX7C antibody has been cited in one knockout/knockdown publication, providing strong evidence for specificity .

• Verify immunogen sequence conservation across species. Both antibodies were generated using fusion proteins (Ag1989 for COX7C and Ag1988 for COX7B) , so alignment of these sequences across target species can predict potential cross-reactivity.

What are the considerations for combining COX7 antibodies with other mitochondrial markers in multiplex studies?

When designing multiplex studies incorporating COX7 antibodies with other mitochondrial markers, researchers should consider:

• Antibody host species and isotype: Both COX7B and COX7C antibodies are rabbit polyclonal IgG antibodies , which limits direct co-staining with other rabbit-derived antibodies unless specialized detection systems are employed.

• Subcellular localization: COX7 proteins are localized to mitochondria, specifically as components of the respiratory chain complex IV. This allows for co-localization studies with other mitochondrial markers but requires careful selection of complementary antibodies that target distinct mitochondrial structures or functions.

• Fluorophore selection for immunofluorescence: The COX7C antibody has been validated for immunofluorescence in MCF-7 cells at dilutions of 1:20-1:200 . When designing multiplex experiments, spectral overlap between fluorophores must be minimized, particularly if using fluorophore-conjugated primary antibodies.

• Impact of fixation and permeabilization: Mitochondrial antigens can be sensitive to fixation conditions. While both antibodies work with standard fixation protocols, optimization may be required when combining with antibodies targeting more sensitive epitopes.

• Quantitative considerations: When performing quantitative analyses of co-localization or expression levels, calibration controls should be included to account for potential differences in antibody affinity and detection sensitivity.

What is the significance of the discrepancy between calculated and observed molecular weights of COX7 proteins?

The discrepancy between calculated and observed molecular weights of COX7 proteins, particularly for COX7C, presents an interesting research question. While COX7C has a calculated molecular weight of 7 kDa (63 amino acids), it is typically observed at 15-28 kDa in Western blot applications . COX7B shows better concordance between its calculated (9 kDa, 80 amino acids) and observed (9 kDa) molecular weights .

Several factors may contribute to this discrepancy:

• Post-translational modifications: COX7C may undergo modifications such as glycosylation, phosphorylation, or ubiquitination that increase its apparent molecular weight.

• Incomplete denaturation: COX7C might retain some secondary structure or remain associated with other proteins even under denaturing conditions, leading to reduced electrophoretic mobility.

• Protein complexes: As components of the larger cytochrome c oxidase complex, COX7 proteins may form stable interactions with other subunits that persist partially during sample preparation.

• Tissue-specific modifications: The search results indicate successful detection of COX7C in multiple tissues (mouse ovary, human skeletal muscle) , which may exhibit tissue-specific modifications affecting molecular weight.

Researchers investigating this discrepancy should consider employing mass spectrometry to accurately determine the molecular composition of the protein, perform phosphatase or glycosidase treatments to identify specific modifications, and use alternative detergents or denaturation conditions to ensure complete protein unfolding prior to electrophoresis.